The latest news, announcements and press releases from Antengene Corp.
Antengene Corporation Limited (Antengene) has entered a global clinical collaboration with MSD (Merck & Co., Inc.) to evaluate the combination of ATG-022 and MSD’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in patients with advanced solid tumors.
This is the News section of the company profile page for Antengene Corp on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.